Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.

Alnylam Pharma ( ($ALNY) ) has issued an update. On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of ...

The company was one of many to get letters last month from the US Food and Drug Administration calling out what the agency ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on September 19 and ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY) has pulled a television ad for its drug Amvuttra (vutrisiran) after the U.S. FDA determined the spot was misleading. Amvuttra is approved for two heart ...

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 ...

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam ...

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam ...

Alnylam joins Illumina and NashBio’s Alliance for Genomic Discovery to expand its 250,000 genome dataset and fuel RNAi research.